Picture loading failed.

Anti-CD274 therapeutic antibody (Pre-made Retlirafusp biosimilar,Whole mAb Fusion) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).



Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-481-1mg 1mg Inquiry
GMP-Bios-ab-481-10mg 10mg Inquiry
GMP-Bios-ab-481-100mg 100mg Inquiry
GMP-Bios-ab-481-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-CD274 therapeutic antibody (Pre-made Retlirafusp biosimilar,Whole mAb Fusion)
INN Name Retlirafusp
TargetCD274
FormatWhole mAb Fusion
Derivation
Species ReactivityHuman
CH1 IsotypeIgG4
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-I/II
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2020
Year Recommendedna
CompaniesJiangsu Hengrui Medicine
Conditions Approvedna
Conditions ActivePancreatic cancer;Solid tumours;Head and neck squamous cell carcinoma
Conditions Discontinuedna
Development Techna